Altered response to thyroid hormones by prostate and breast cancer cells M. B. MartinezM. RuanL. A. Fitzpatrick ORIGINAL ARTICLE Pages: 93 - 102
Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation John D. RobertsElizabeth A. PoplinRichard Moran ORIGINAL ARTICLE Pages: 103 - 110
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen Jeremy P. BraybrookeSue HoulbrookDenis C. Talbot ORIGINAL ARTICLE Pages: 111 - 119
Different microtubule network alterations induced by pachymatismin, a new marine glycoprotein, on two prostatic cell lines Suleeporn SangrajrangMohamed ZidaneArlette Fellous ORIGINAL ARTICLE Pages: 120 - 126
Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer Daniela GalloCristiano FerliniGiovanni Scambia ORIGINAL ARTICLE Pages: 127 - 132
Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59) Jiro ShibataToshiyuki TokoYuji Yamada ORIGINAL ARTICLE Pages: 133 - 141
Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy N. L. LehmanP. V. Danenberg ORIGINAL ARTICLE Pages: 142 - 148
Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme Yoshitaka NaritaAkio AsaiTakaaki Kirino ORIGINAL ARTICLE Pages: 149 - 156
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function Claire MassariSilvano BrienzaGérard Bastian ORIGINAL ARTICLE Pages: 157 - 164
Impact of the simultaneous administration of the (+)- and (−)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (−)-tetrahydrofolic acid Eberhard SchleyerKarl Lenhard RudolphWolfgang Kern ORIGINAL ARTICLE Pages: 165 - 171
In vitro antioxidant properties of amifostine (WR-2721, Ethyol) Fulvio MarzaticoCamillo PortaLaura Castagna ORIGINAL ARTICLE Pages: 172 - 176
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study Ofer MerimskyIsaac Mellerfor the Israeli Soft Tissue and Bone Sarcoma Treatment Groups CLINICAL TRIAL REPORT Pages: 177 - 181